Meta-analyses were performed with Review Manager 5.4.<h4>Results</h4>Trilaciclib significantly reduced the incidence of severe neutropenia (SN) and febrile neutropenia (FN), shortened SN duration, and decreased the need for erythropoiesis-stimulating agents (ESAs), granulocyte colony-stimulating factor (G-CSF) and red-blood-cell (RBC) transfusions while lowering anemia rates. The gene discussed is CSF3; the disease is Decreased total neutrophil count.